SCINTIX® technology is a novel therapy for patients with tumors in the lung or bone arising from primary and metastatic cancer. This breakthrough technology uses live, continuously updated data throughout the entire treatment session to determine where to deliver radiotherapy.
DOWNLOAD WHITEPAPER
Initially cleared to use with fludeoxyglucose F18 (FDG), SCINTIX therapy is the only platform that can leverage the rapidly expanding universe of novel radiopharmaceuticals to more accurately target cancer over other imaging modalities.
SCINTIX therapy can treat tumors in the lung or bone from any stage of cancer with conformal dose delivery and potentially smaller margins, resulting in less toxicity that should improve patient outcomes.
Our SCINTIX technology tracks both periodic and non-periodic tumor motion caused by physiologic processes, and motion you don’t expect, like that from surprise shifts in patient position.
Initially cleared to use with fludeoxyglucose F18 (FDG), SCINTIX therapy is the only platform that can leverage the rapidly expanding universe of novel radiopharmaceuticals to more accurately target cancer over other imaging modalities.
SCINTIX therapy can treat tumors in the lung or bone from any stage of cancer with conformal dose delivery and potentially smaller margins, resulting in less toxicity that should improve patient outcomes.
Our SCINTIX technology tracks both periodic and non-periodic tumor motion caused by physiologic processes, and motion you don’t expect, like that from surprise shifts in patient position.
The RefleXion® X1 with SCINTIX technology marries PET and CT, proven modalities for visualizing cancer, with radiotherapy, one of the most effective ways of treating cancer, in a dual-treatment modality platform.
By combining radiotherapy and PET-CT in a novel way,
we can find and treat cancer using its own emissions.
Learn more about SCINTIX biology-guided radiotherapy and RefleXion’s vision.
See how SCINTIX therapy expands radiotherapy to metastatic patients.
Take a deeper dive into the RefleXion X1 platform.
SCINTIX therapy uses PET – the gold standard in cancer imaging – in a new way to solve the conundrum of tumor motion. A single radiopharmaceutical injection turns each cancer into a biological beacon that communicates data about the cancer’s location, via a continuous stream of emissions. As the tracer accumulates in tumors, onboard PET detectors on the X1 machine sense the emissions and use this data to deliver treatment with sub-second latency.
Watch Video
For cancer patients with tumors in the lung or bone, SCINTIX biology-guided radiotherapy creates a new treatment option. SCINTIX therapy brings the cost effectiveness and efficacy of radiotherapy to more advanced staged cancers. Because SCINTIX technology uses tumor emissions created during treatment to control delivery, clinicians no longer construct plans for moving tumors using an ITV approach that irradiates a large volume. Instead, the PTV may be more conformal to spare healthy tissue and preserve dose for additional tumors.
WATCH VIDEO
SCINTIX biology-guided radiotherapy elevates the performance of radiopharmaceuticals from a diagnostic tool to one that precisely controls treatment delivery. Initially compatible with FDG, RefleXion seeks to enable SCINTIX therapy for other disease-specific tracers. We have forged collaboration agreements with industry-leading radiopharmaceutical manufacturers to develop both fluorine and gallium PSMA tracers that will one day expand SCINTIX therapy to include all stages of prostate cancer.
WATCH VIDEO
The RefleXion X1 with SCINTIX therapy is the only hybrid platform offering both biologic technology for tumors in motion and anatomic capabilities via its onboard fan-beam kVCT. The X1 fits in most standard vaults with minimum shielding requirements to reduce the implementation and start-up costs.
A closer look at the proprietary technologies that combine to create our game-changing approach to cancer treatment.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View our latest peer-reviewed articles and abstracts.
Learn more about our PREMIER registry for patients with all stages of cancer.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View our latest peer-reviewed articles and abstracts.
Learn more about our PREMIER registry for patients with all stages of cancer.
Let us tell you more.
Contact UsStay up to date.
Sign Up